CAS · 920509-32-6
Product Overview
Resmetirom is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance: | White to yellow or orange powder |
|---|---|
| Assay (calculated on the dried basis): | 98.0%~102.0% |
| Solubility: | Freely soluble in dimethyl sulfoxide, slightly soluble in ethanol, practically insoluble in water |
| Appearance of solution: | The solution is clear and not more intensely colored than reference solution Y6 |
| Identification: | IR: The infrared absorption spectrum of the sample shall be consistent with that of the reference substance. HPLC: The retention time of the major peak of the sample solution corresponds to that of the standard solution, as obtained in the Assay. |
| Heavy metal: | 20ppm max |
| Loss on drying: | 0.5% max |
| Residue on ignition: | 0.1% max |
| Related substances: | Single impurity: 0.10% max Total impurities: 0.50% max |
| Residual solvent: | Acetone: 0.50% max Ethanol: 0.50% max Methyl isobutyl ketone: 0.45% max N,N-Dimethylacetamide: 0.109% max |
| Microbial Contamination: | Total Aerobic Microbial Count: 10³ CFU/g max Total Combined Yeasts/Molds Count: 10² CFU/g max Escherichia coli: cannot be detected |
Applications
1. Treatment of NASH (Non-Alcoholic Steatohepatitis)
Primary application of Resmetirom.
NASH is a severe form of non-alcoholic fatty liver disease (NAFLD) characterized by fat accumulation, inflammation, and fibrosis.
Resmetirom activates THR-β in the liver, promoting lipid metabolism and reducing hepatic fat content, inflammation, and fibrosis without the systemic side effects of traditional thyroid hormones.
2. Dyslipidemia and Hypercholesterolemia
Resmetirom lowers LDL-C, triglycerides, and apolipoprotein B by enhancing hepatic uptake and clearance of cholesterol and triglyceride-rich particles.
Useful in familial hypercholesterolemia, mixed dyslipidemia, and atherosclerosis prevention.
3. Metabolic Syndrome and Obesity
By improving liver function and lipid profiles, Resmetirom shows potential in broader metabolic disorders.
Supports weight management indirectly through lipid modulation.
4. Investigational Use in Cardiovascular Disease
Due to its lipid-lowering effect and impact on hepatic steatosis, Resmetirom is being explored as a cardiometabolic health promoter.
Benefits
✅ Selective THR-β Agonism
Unlike natural thyroid hormones that act on both THR-α and THR-β, Resmetirom selectively activates THR-β, which is predominantly expressed in liver tissue.
This minimizes cardiac and skeletal muscle side effects often seen with thyroid hormone therapy.
✅ Non-Hormonal Side Effects
Does not significantly affect heart rate or bone density, making it safer for long-term use compared to T3 or T4 derivatives.
✅ Liver-Targeted Action
Optimized for hepatic distribution, making it ideal for liver-centric conditions like NAFLD and NASH.
✅ Clinically Proven Fat Reduction
Phase 2 and 3 clinical trials have demonstrated:
~30% relative reduction in liver fat (MRI-PDFF)
Reduction in fibrosis biomarkers
Improvement in liver enzymes (ALT, AST)
✅ Orally Bioavailable
Resmetirom is taken orally once daily, offering patient compliance advantages over injectable or invasive treatments.
✅ Potential Disease-Modifying Effects
Not only improves biomarkers, but potentially halts or reverses disease progression in NASH and related liver pathologies.
Conclusion
Resmetirom (CAS 920509-32-6) represents a new class of liver-targeted metabolic modulators that address the growing burden of non-alcoholic steatohepatitis (NASH) and dyslipidemia. Its selective action on THR-β makes it a safe and effective therapeutic candidate with broad potential across cardiometabolic disorders. If approved, it may be a game-changer in hepatology and metabolic medicine.
Previous
Bepotastine Besilate丨CAS 190786-44-8
Next